Absci Announces Proposed Public Offering of Common Stock
Absci (NASDAQ: ABSI), a clinical-stage biopharmaceutical company leveraging generative AI for therapeutic development, has announced a proposed public offering of $50 million in common stock. The company will also grant underwriters a 30-day option to purchase up to an additional $7.5 million in shares.
The offering will be managed by Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities as joint book-running managers. Proceeds will support Absci's internal program development, platform investment, and general corporate purposes. The offering will be made through an effective shelf registration statement previously filed with the SEC.
Absci (NASDAQ: ABSI), una societ脿 biofarmaceutica in fase clinica che utilizza l'IA generativa per lo sviluppo terapeutico, ha annunciato un offerta pubblica proposta di 50 milioni di dollari in azioni ordinarie. La societ脿 conceder脿 inoltre agli underwriter un'opzione di 30 giorni per acquistare fino a un ulteriore 7,5 milioni di dollari in azioni.
L'offerta sar脿 gestita da Morgan Stanley, J.P. Morgan, Jefferies e TD Securities come joint book-running manager. I proventi sosterranno lo sviluppo interno dei programmi di Absci, gli investimenti nella piattaforma e le finalit脿 aziendali generali. L'offerta sar脿 effettuata tramite una dichiarazione di registrazione a scaffale efficace precedentemente depositata presso la SEC.
Absci (NASDAQ: ABSI), una empresa biofarmac茅utica en fase cl铆nica que utiliza IA generativa para el desarrollo terap茅utico, ha anunciado una oferta p煤blica propuesta de 50 millones de d贸lares en acciones comunes. La compa帽铆a tambi茅n conceder谩 a los colocadores una opci贸n de 30 d铆as para comprar hasta 7,5 millones de d贸lares adicionales en acciones.
La oferta ser谩 gestionada por Morgan Stanley, J.P. Morgan, Jefferies y TD Securities como gestores conjuntos principales. Los ingresos apoyar谩n el desarrollo interno de programas de Absci, la inversi贸n en la plataforma y los prop贸sitos corporativos generales. La oferta se realizar谩 mediante una declaraci贸n de registro en estanter铆a efectiva previamente presentada ante la SEC.
Absci (NASDAQ: ABSI)電� 旃橂鞝� 臧滊皽鞚� 鞙勴暣 靸濎劚順� AI毳� 頇滌毄頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 5,000毵� 雼煬 攴滊鞚� 瓿店皽 氇鞚� 鞝滌晥頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 霕愴暅, 鞚胳垬鞚鸽摛鞐愱矊 30鞚缄皠 於旉皜搿� 750毵� 雼煬旯岇 欤检嫕鞚� 甑Г頃� 靾� 鞛堧姅 鞓奠厴鞚� 攵�鞐暊 鞓堨爼鞛呺媹雼�.
鞚措矆 氇鞚� Morgan Stanley, J.P. Morgan, Jefferies, TD Securities臧� 瓿惦彊 欤缄磤靷 甏�毽暕雼堧嫟. 氇 鞛愱笀鞚� Absci鞚� 雮措秬 頂勲攴鸽灗 臧滊皽, 頂岆灚韽� 韴瀽 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅� 鞓堨爼鞛呺媹雼�. 鞚� 氇鞚� SEC鞐� 鞚挫爠鞐� 鞝滌稖霅� 鞙犿毃頃� 靹犽皹 霌彪 氇呾劯靹滊ゼ 韱淀暣 歆勴枆霅╇媹雼�.
Absci (NASDAQ : ABSI), une soci茅t茅 biopharmaceutique en phase clinique utilisant l'IA g茅n茅rative pour le d茅veloppement th茅rapeutique, a annonc茅 une offre publique propos茅e de 50 millions de dollars en actions ordinaires. La soci茅t茅 accordera 茅galement aux souscripteurs une option de 30 jours pour acheter jusqu'脿 7,5 millions de dollars suppl茅mentaires en actions.
L'offre sera g茅r茅e par Morgan Stanley, J.P. Morgan, Jefferies et TD Securities en tant que chefs de file conjoints. Les fonds serviront 脿 soutenir le d茅veloppement des programmes internes d'Absci, les investissements dans la plateforme et les besoins g茅n茅raux de l'entreprise. L'offre sera r茅alis茅e via une d茅claration d'enregistrement sur 茅tag猫re efficace pr茅c茅demment d茅pos茅e aupr猫s de la SEC.
Absci (NASDAQ: ABSI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das generative KI f眉r die therapeutische Entwicklung nutzt, hat ein vorgeschlagenes 枚ffentliches Angebot von 50 Millionen US-Dollar in Stammaktien angek眉ndigt. Das Unternehmen wird den Underwritern au脽erdem eine 30-t盲gige Option einr盲umen, bis zu weitere 7,5 Millionen US-Dollar an Aktien zu erwerben.
Das Angebot wird von Morgan Stanley, J.P. Morgan, Jefferies und TD Securities als gemeinsame Bookrunner verwaltet. Die Erl枚se sollen die interne Programmentwicklung von Absci, Investitionen in die Plattform und allgemeine Unternehmenszwecke unterst眉tzen. Das Angebot erfolgt 眉ber eine zuvor bei der SEC eingereichte wirksame Shelf-Registrierungserkl盲rung.
- None.
- Offering will likely cause dilution for existing shareholders
- Stock price may face pressure due to increased share supply
Insights
Absci is raising $50M through stock offering to fund drug development and platform investment, likely diluting existing shareholders.
Absci Corporation (ABSI) has announced a $50 million public offering of common stock with an additional $7.5 million option for underwriters. This capital raise comes as the company transitions from a pure AI platform to a clinical-stage biopharmaceutical company with its own drug pipeline. The offering will dilute existing shareholders but provides crucial funding for three key areas: advancing internal drug programs, continued investment in their Integrated Drug Creation platform, and general working capital.
The involvement of major underwriters including Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities lends credibility to the offering, suggesting institutional confidence in Absci's direction. However, the company's use of the phrase "subject to market and other conditions" indicates uncertainty about final terms and timing, which will be detailed in a forthcoming prospectus.
For investors, this offering represents a double-edged sword: dilution of ownership percentage and potential downward pressure on share price in the near term, but enhanced financial stability and development capabilities for future growth. The company's strategic pivot from platform technology to developing its own therapeutic candidates requires significant capital, making this raise a logical step in their business evolution. The ability to successfully close this offering will serve as a meaningful indicator of market confidence in Absci's AI-driven approach to drug discovery and development.
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (鈥淎bsci鈥�), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, announced today that it has commenced an underwritten public offering of
Absci intends to use the net proceeds from the offering to fund the advancement of its internally developed programs, continued investment in its Integrated Drug Creation鈩� platform, and for working capital and other general corporate purposes.
Morgan Stanley, J.P. Morgan, Jefferies, and TD Securities (USA) LLC are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.
The shares of common stock are being offered by Absci pursuant to an effective shelf registration statement on Form S-3 (File No. 333-267043) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on August 24, 2022 and became effective on September 2, 2022. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that will form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by telephone: (866) 718-1649, or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] and [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (833) 297- 2926, or by email at [email protected]; or by accessing the SEC鈥檚 website at www.sec.gov. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Absci鈥檚 headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Absci鈥檚 anticipated public offering. The words 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渃ould,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渆stimate,鈥� 鈥渟eek,鈥� 鈥減redict,鈥� 鈥渇uture,鈥� 鈥減roject,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� 鈥渢arget鈥� and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Any forward-looking statements in this press release, such as the intended offering terms, are based on management鈥檚 current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, Absci鈥檚 intention to grant the underwriters an option to purchase additional shares and the intended use of proceeds. These and other risks and uncertainties are described in greater detail in the section entitled 鈥淩isk Factors鈥� in Absci鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Absci鈥檚 other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the proposed public offering expected to be filed with the SEC. In addition, any forward-looking statements contained in this press release represent Absci鈥檚 views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Absci explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
[email protected]
Media Contact
[email protected]
FAQ
How much is Absci (ABSI) planning to raise in its public offering?
What will Absci use the proceeds from the stock offering for?
Who are the underwriters for Absci's public offering?
When was Absci's shelf registration statement filed and effective?
What type of company is Absci (ABSI)?
